Ulf Grawunder
Directeur/Membre du Conseil chez WUXI XDC CAYMAN INC.
Provenance du réseau au premier degré de Ulf Grawunder
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
University of Basel
21
| College/University | Other Consumer Services | 21 |
20
| Public Company | Pharmaceuticals: Major | 20 |
University of Bayreuth
9
| College/University | Other Consumer Services | 9 |
| Public Company | Miscellaneous Commercial Services | 9 | |
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.
7
| Subsidiary | Biotechnology | 7 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.
2
| Private Company | Investment Managers | 2 |
T-CURX GmbH
1
| Private Company | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Ulf Grawunder via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Tsinghua University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| WUXI BIOLOGICS (CAYMAN) INC. | Biotechnology | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| Chinese Academy of Sciences | College/University | Graduate Degree Graduate Degree Corporate Officer/Principal | |
| Wuhan University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Hong Kong Institute of Certified Public Accountants
 Hong Kong Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Hong Kong Institute of Certified Public Accountants operates under the professional accountant’s ordinance and works in the public interest. It offers CPA qualification programme and promulgating financial reporting, auditing and ethical standards in Hong Kong. The company was founded on January 1, 1973 and is headquartered in Hong Kong. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| PDL BIOPHARMA, INC. | Biotechnology | Public Communications Contact Director/Board Member | |
| University of Delaware | College/University | Undergraduate Degree Doctorate Degree | |
| University of St. Gallen | College/University | Masters Business Admin Corporate Officer/Principal | |
| Beijing Normal University | College/University | Undergraduate Degree Undergraduate Degree | |
| WUXI APPTEC CO., LTD. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| East China University of Science & Technology | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Zurich | College/University | Doctorate Degree Doctorate Degree | |
| WUXI PHARMATECH (CAYMAN) INC. (ADR) | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| UBS | Investment Managers | Director/Board Member Comptroller/Controller/Auditor | |
| XENCOR, INC. | Biotechnology | Corporate Officer/Principal Private Equity Analyst | |
Peking University
 Peking University Other Consumer ServicesConsumer Services Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China. | College/University | Undergraduate Degree Undergraduate Degree | |
Abmaxis, Inc.
 Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
| AXALTA COATING SYSTEMS LTD. | Industrial Specialties | Corporate Officer/Principal Comptroller/Controller/Auditor | |
| NGM BIOPHARMACEUTICALS, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| Zhongshan Hospital Fudan University | College/University | Doctorate Degree Graduate Degree | |
Crown Bioscience, Inc.
 Crown Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Vischer AG
 Vischer AG Miscellaneous Commercial ServicesCommercial Services Vischer AG provides legal advisory services. The private company is based in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| BANK CLER AG | Regional Banks | President Director/Board Member | |
| BASLER KANTONALBANK | Regional Banks | Chairman Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| Europa Institute at the University of Zurich | Director/Board Member Director/Board Member | ||
| THYSSENKRUPP AG | Steel | Director/Board Member Sales & Marketing | |
| The Leonard N Stern School of Business | College/University | Masters Business Admin Graduate Degree | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Secretary Chairman | |
| Harvard Medical School | College/University | Corporate Officer/Principal | |
| The University of Texas Southwestern Medical Center | College/University | Corporate Officer/Principal | |
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Biotechnology | Chief Executive Officer | |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
| The University of Tennessee Health Science Center | College/University | Doctorate Degree | |
Cooperatieve Rabobank UA (London Branch)
 Cooperatieve Rabobank UA (London Branch) Regional BanksFinance Cooperatieve Rabobank U.A. provides banking services. It offers deposits, personal banking, electronic financial transactions, investment advices, short term and long term credits, and several other services. The company is headquartered in London, the United Kingdom. | Regional Banks | Corporate Officer/Principal | |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
Bankers Trust & Co.
 Bankers Trust & Co. Investment Trusts/Mutual FundsMiscellaneous Part of Deutsche Bank AG, Bankers Trust & Co. is a company that provides trust services. The company is based in New York, NY. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Deutsche Bank AG (London Branch)
 Deutsche Bank AG (London Branch) Regional BanksFinance Deutsche Bank AG provides corporate banking and investment services. It offers asset and wealth management, corporate banking and securities and global transaction banking solutions. The company was founded in 1873 and is headquartered in London, the United Kingdom. | Regional Banks | Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal | |
Topas Therapeutics GmbH
 Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany. | Pharmaceuticals: Major | Chairman | |
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Corporate Officer/Principal | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
Casebia Therapeutics LLP
 Casebia Therapeutics LLP Miscellaneous Commercial ServicesCommercial Services Casebia Therapeutics LLP provides physical, chemical, and analytical testing services. The British company was founded in 2016, and Jim Burns has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Director/Board Member | |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member | |
Joyn Bio LLC
 Joyn Bio LLC Real Estate DevelopmentFinance Joyn Bio LLC is a joint venture between Leaps by Bayer and Ginkgo Bioworks that engineers microbes to improve naturally occurring processes in agriculture. The company is based in Boston, MA, and has two sites for leading scientists with diverse backgrounds. The company's focus is on developing probiotics for plants to provide growers with next-generation solutions to their biggest challenges. The company's first area of focus is on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture's reliance on nitrogen fertilizer and its environmental impact. | Real Estate Development | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 20 |
| Chine | 11 |
| Suisse | 9 |
| Royaume-Uni | 7 |
| Allemagne | 6 |
Sectorielle
| Health Technology | 17 |
| Consumer Services | 15 |
| Commercial Services | 9 |
| Finance | 9 |
| Process Industries | 2 |
Opérationnelle
| Director/Board Member | 198 |
| Corporate Officer/Principal | 129 |
| Undergraduate Degree | 44 |
| Doctorate Degree | 38 |
| Chairman | 36 |
Relations les plus connectées
| Insiders | |
|---|---|
| Jürgen Eckhardt | 34 |
| Cuong Viet Do | 27 |
| Simon Jules Nebel | 23 |
| Beatrice Weder di Mauro | 19 |
| Mervyn Turner | 18 |
| Nicole Onetto | 17 |
| Zhi Sheng Chen | 15 |
| Stewart John Hen | 15 |
| Erich Schlick | 15 |
| Michael Claus Wisser | 15 |
| Marc Oliver Heß | 14 |
| Remy Hauser | 13 |
| Bertrand Damour | 12 |
| Yannick Hausmann | 12 |
| Oliver M. Bartholet | 12 |
- Bourse
- Insiders
- Ulf Grawunder
- Connexions Sociétés
